Crohn's Pipeline: Janssen Seeks New Niche For Stelara As Biologics Use Rises
This article was originally published in Scrip
Executive Summary
Doctors who treat Crohn's disease are prescribing biologics more frequently than in the past to quickly reduce inflammation, but they're searching for alternatives to tumor necrosis factor (TNF) inhibitors to cut the side effect risks, and that is where the Johnson & Johnson subsidiary Janssen Biotech Inc. may find its best niche for Stelara (ustekinumab).
You may also be interested in...
New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs
J&J’s Janssen Biotech subsidiary won FDA approval for the IL-12/IL-23 inhibitor Stelara to treat Crohn’s disease, giving it a second-line position alongside anti-TNF therapies for patients in need of new options.
Bundled Contracts To Defend Against Biosimilars May Face Payer Skepticism
J&J plans to rely on its broad portfolio to contract favorably in a 'post-biosimilar world,' but cross-category bundling is generally discouraged by payers.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.